The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Yekeduz, Emre; Tural, Deniz; Erturk, Ismail; Karakaya, Serdar; EROL, CİHAN; Ercelep, Ozlem; Arslan, Cagatay; Sever, Ozlem; KILIÇKAP, SAADETTİN; Senturk Oztas, Nihan; Kucukarda, Ahmet; Can, Orcun; Oksuzoglu, Berna; ŞENDUR, MEHMET; Karadurmus, Nuri; ÜRÜN, YÜKSEL

doi:10.1007/s00432-022-04055-5

The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Atıf İçin Kopyala

Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 148 Sayı: 12
Basım Tarihi: 2022
Doi Numarası: 10.1007/s00432-022-04055-5
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.3537-3546
Anahtar Kelimeler: Immunotherapy, Renal cell carcinoma, Biomarker, TO-LYMPHOCYTE RATIO, INDEX SII, PROGNOSTIC-FACTORS, THERAPIES, MRCC
Ankara Üniversitesi Adresli: Evet

Özet

Background Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.